Biotechnology Press Release
|04/20/2020 - 11:36||
TUKYSA (tucatinib), FDA Approved for Treatment of Advanced Unresectable or Metastatic HER2 Positive Breast Cancer, Available at Biologics by McKesson
CARY, N.C., April 20, 2020—Biologics by McKesson, an independent specialty pharmacy for oncology and other rare and complex therapeutic areas, has been selected by Seattle Genetics as a specialty pharmacy provider for TUKYSATM (tucatinib) for the treatment of HER2 positive breast cancer.
|04/20/2020 - 11:09||
FIRST COVID-19 PATIENT TREATED UNDER EMERGENCY USE IND AT PROVIDENCE SAINT JOHNS HEALTH CENTER USING STEMEDICA ISCHEMIA-TOLERANT ALLOGENEIC MESENCHYMAL BONE MARROW CELLS
SANTA MONICA – April 20, 2020 – A single patient, emergency Investigational New Drug (IND) use was cleared by the U.S. Food and Drug Administration for the treatment of severe lung injury due to COVID-19 at the Providence Saint John’s Health Center, Santa Monica, CA with intravenous administration of ischemia-tolerant allogeneic mesenchymal bone marrow cells (itMSCs) manufactured by Stemedica Cell Technologies, Inc.
|04/20/2020 - 10:24||
Myriad Genetics Announces Publication of a Meta-Analysis Demonstrating the Clinical Utility of the GeneSight Psychotropic Test in People with Major Depressive Disorder
The article titled, “The Clinical Utility of Combinatorial Pharmacogenetic Testing for Patients with Depression: A Meta-Analysis,” appeared online in the journal Pharmacogenomics.
|04/19/2020 - 21:34||
Picking Up Threads of Cotton Genomics
Come harvest time, the cotton fields look like popcorn is literally growing on plants, with fluffy white bolls bursting out of the green pods in every direction. There are 100 million families around the world whose livelihoods depend on cotton production, and the crop’s annual economic impact of $500 billion worldwide underscores its value and importance in the fabric of our lives.
|Joint Genome In...|
|04/19/2020 - 09:24||
Mercks Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19
As America?s biopharmaceutical companies work around the clock to combat COVID-19, a disease caused by a novel strain of coronavirus, now is an important time to consider how we can prepare for the next public health emergency: Antimicrobial resistance (AMR).
|04/18/2020 - 09:23||
NW Bio To Discuss Projected Schedule For Data Lock, Unblinding and Top Line Data From Its Phase 3 Clinical Trial At Annual Shareholder Meeting
BETHESDA, Md., April 18, 2020 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that its CEO, Linda Powers, will discuss the projected schedule for reaching data lock, unblinding and reporting of top line data from its 331-patient Phase 3 trial of DCVax®-L for Glioblastoma brain cancer at the Company’s 2019 Annual Meeting. The Meeting is being held virtually due to the current public health crisis.
|04/17/2020 - 17:23||
How brain tumors escape therapy, antibiotic resistance on the move, guidance for CRISPR guides, and more
Welcome to the April 17, 2020 installment of Research Roundup, a recurring snapshot of recent studies published by scientists at the Broad Institute and their collaborators.
|04/17/2020 - 17:17||
Polis Orders the Closure of Health Food Stores
WASHINGTON – Governor Polis in contravention of guidance from the Department of Homeland Security (DHS), ordered the closure of health food stores during the COVID-19 public health crisis. Governor Polis’s order will restrict access to a wide range of essential products sold by health food stores, including, water, electrolytes, nutritional supplements, healthy food options, and other health-related products such as hand sanitizer.
|04/17/2020 - 17:11||
Ochsner Health and BioInfoExperts Complete First Genomic Sequences of COVID-19 from New Orleans
Scientists from BioInfoExperts LLC (BIE) and Ochsner Health have completed the first whole genome sequences of the SARS-CoV-2 coronavirus from the New Orleans area. By breaking down the virus to its most basic building blocks, researchers are one step closer to understanding viral spread across the state. One additional sequence originating from Baton Rouge has been released by the Centers for Disease Control.
|Ochsner Health ...|
|04/17/2020 - 16:38||
InVivo Therapeutics Announces Closing of $3.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
The gross proceeds to the Company from the registered direct offering were approximately $3.0 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital, business development activities, and general corporate purposes.
|04/17/2020 - 16:12||
Pioneering project to reduce Monkey Fever deaths
New research that is enabling scientists to predict outbreaks of Kyasanur Forest Disease in India could reduce deaths and provide a template for tackling other infections that spread between animals and humans.
|Centre for Ecol...|
|04/17/2020 - 02:17||
Oasmia Nomination Committee suggest changes in the Board of Directors
The Nomination Committee of Oasmia propose changes in the company´s Board of Directors to be decided on an Extraordinary General Meeting (EGM) to be held on May 14, 2020. Current board member Anders Härfstrand is proposed to be the new Chairman of the Board and Birgit Stattin Norinder is suggested to be a new member of the Board. Jörgen Olsson, current Chairman of the Board, and Gunilla Öhman, current Board member, will leave the Board.
|04/17/2020 - 00:52||
Sangamo Appoints D. Mark McClung as Executive Vice President and Chief Business Officer
Mr. McClung will oversee commercial strategic planning, alliance management and corporate and business development.
|04/16/2020 - 19:58||
Tabula Rasa HealthCare and CQuentia Expand Partnership with COVID-19 Test Kit Distribution Agreement
The agreement provides TRHC with access to COVID-19 (SARS-CoV-2 RNA) testing kits for distribution to Programs of All-Inclusive Care for the Elderly (PACE) through TRHC’s CareKinesis Pharmacy.
|Tabula Rasa Hea...|
|04/16/2020 - 17:44||
Partners HealthCare, Biogen, and Broad Institute of MIT and Harvard Launch Consortium to Build and Share a COVID-19 Biobank
Partners HealthCare, Biogen Inc., and Broad Institute of MIT and Harvard today announced a consortium that will build and share a COVID-19 biobank. The biobank will help scientists study a large collection of de-identified biological and medical data to advance knowledge and search for potential vaccines and treatments.
|04/16/2020 - 15:07||
Illumina Makes Software Toolkit Available Free of Charge to Support Worldwide Efforts to Combat COVID-19
Accelerates the detection and identification of viral sequences and seamless submission to critical databases.
|04/16/2020 - 09:52||
Covid-19 tracker helps visualise cases in Scotland
A dashboard pulling together data from several sources on the Covid-19 outbreak in Scotland provides a picture of how the situation is developing.
|04/16/2020 - 09:07||
Broad Institute partners with City of Cambridge to pilot COVID-19 surveillance in nursing facilities
The program is testing each staff member and resident in the city’s seven nursing facilities to help prevent and treat COVID-19
|04/16/2020 - 05:15||
Provectus Announces PV-10 Liver Cancer Presentation in ePoster Gallery of Society of Interventional Radiology (SIR) 2020 Annual Scientific Meeting
KNOXVILLE, TN, April 16, 2020 ( ) — Provectus (OTCQB: PVCT) today said that data from its clinical trial of autolytic cancer immunotherapy PV-10 (rose bengal disodium) as a single-agent and in combination with immune checkpoint blockade for the treatment of primary or metastatic tumors of the liver (NCT00986661) was uploaded to the SIR 2020 ePoster Gallery of the canceled Society of Interventional Radiology (SIR) 2020 Annual Scientific Meeting, which was originally scheduled to be held March 28-April 2, 2020 in Seattle, Washington.
|04/16/2020 - 02:54||
Genetics expertise could transform fish production
A recent review of research highlights how genetics can support development of sustainable aquaculture for global food security.
|04/15/2020 - 17:25||
InVivo Therapeutics Announces $3.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
The gross proceeds to the Company from the registered direct offering are expected to be $3.0 million, before deducting the placement agent’s fees and other offering expenses payable by InVivo Therapeutics. The Company intends to use the net proceeds from this offering for working capital, business development activities, and general corporate purposes.
|04/15/2020 - 11:26||
FDA Approves Initiation of Phase III Study of Lenzilumab in COVID-19 patients
Durrant continued, “Lenzilumab has demonstrated an excellent safety and tolerability profile in other disease settings, including severe asthma. As the only company that as been working on prevention of cytokine storm through GM-CSF neutralization for nearly three years, we have published extensively in this field and filed extensive IP.
|CTI Clinical Tr...|
|04/15/2020 - 08:55||
FDA Authorizes Initiation of a Phase 2 Trial Evaluating MultiStem Cell Therapy in Trauma Patients
Memorial Hermann-Texas Medical Center in Houston, Texas, one of the busiest Level 1 trauma centers in the United States, intends to conduct the trial. The study represents another important application of the company’s MultiStem cell therapy in the critical care area, targeting the severe inflammatory responses associated with poor outcomes.
|04/15/2020 - 06:51||
FDA Approves Initiation of Humanigens Phase III Study of Lenzilumab in COVID-19 Patients
Phase III study enrollment to focus on adult, hospitalized patients with COVID-19 pneumonia and at high risk of progression to respiratory failure.
|04/15/2020 - 06:18||
Athersys Announces Pricing of Public Offering of Common Stock
Athersys, Inc. (NASDAQ: ATHX) (Athersys) today announced the pricing of its previously announced underwritten public offering of its common stock, par value $0.001 per share (Common Stock), at a price to the public of $2.25 per share, for a total of 22,250,000shares.